TG Therapeutics Inc (TGTX.OQ)
TGTX.OQ on NASDAQ Stock Exchange Capital Market
11.57USD
20 Aug 2018
11.57USD
20 Aug 2018
Change (% chg)
$0.03 (+0.22%)
$0.03 (+0.22%)
Prev Close
$11.55
$11.55
Open
$11.80
$11.80
Day's High
$11.80
$11.80
Day's Low
$11.45
$11.45
Volume
171,757
171,757
Avg. Vol
224,689
224,689
52-wk High
$17.30
$17.30
52-wk Low
$7.25
$7.25
About
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered... (more)
Overall
| Beta: | 1.34 |
| Market Cap(Mil.): | $846.68 |
| Shares Outstanding(Mil.): | 68.84 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| TGTX.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 85.68 | 32.76 |
| EPS (TTM): | -1.95 | -- | -- |
| ROI: | -129.83 | 1.78 | 14.61 |
| ROE: | -133.51 | 3.28 | 16.33 |
BRIEF-TG Therapeutics Reports Qtrly Loss Per Share Of $0.59
* TG THERAPEUTICS, INC. PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS
Competitors
| Price | Chg | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $136.88 | +2.41 |
| Novartis AG (NOVN.S) | CHF82.88 | -- |
| Roche Holding Ltd. (ROG.S) | CHF242.00 | -- |
| Roche Holding Ltd. (RO.S) | CHF245.80 | -- |
| Merck & Co., Inc. (MRK.N) | $70.17 | +1.11 |
| Bayer AG (BAYGn.DE) | €80.78 | -- |
| Bayer AG (BAYE.F) | -- | -- |
| Sanofi SA (SASY.PA) | €73.43 | -- |
| Abbott Laboratories (ABT.N) | $64.64 | -0.08 |
| Alexion Pharmaceuticals, Inc. (ALXN.OQ) | $116.17 | +0.17 |
Estimates